Cardiol Therapeutics Inc. (TSX:CRDL), a biotechnology company developing proprietary formulations that will treat life-threatening diseases, was featured on BNN Bloomberg’s Market Call with Robert McWhirter. Cardiol uses CBD in its drug formulations due to CBDs anti-inflammatory properties, which could help reduce inflammation in human hearts. The company has teamed up with the University of Alberta to develop an encapsulation process that utilizes nanotechnology to enhance the compatibility of the drugs with the aqueous blood circulation, improve pharmacokinetics and increase drug concentration at the site of disease.

Cardiol also has a partnership with Noramco, a global leader in the manufacturing and supply of controlled drug substance APIs. Under its long-term, exclusive supply agreement, Cardiol will be able to manufacture and supply pure pharmaceutical CBD for Canada and Mexico. According to McWhirter, Cardiol believes that they will be able to produce one million grams of synthetic CBD within 2019, which will allow them to bypass provincial suppliers and licensed producers who are struggling to supply the Canadian cannabis market.


If Cardiol can produce one million grams of CBD and also negotiate supply agreements with Shoppers Drug Mart, for instance, McWhirter believes that the company will be able to meet their quota and start selling their drug formulation. He also thinks that Cardiol will be looking at establishing a US partner to capitalize on the hemp and CBD market there and meet the demand for cannabis-based therapies in both Canada and Mexico.

To view the full video, click here.

Click here to connect with Cardiol Therapeutics Inc. (TSX:CRDL) for an Investor Presentation. 

As investors continue to prioritize cannabis opportunities in the US, market watchers expect mergers and acquisitions (M&A) to play a role in the future for Canadian companies.

A consolidation trend has been expected in the Canadian cannabis space for some time now based on the size of the market compared to the number of operations in the country.

Keep reading... Show less

The product will include polyphenols known to have significant health benefits.

BioHarvest Sciences Inc. (CSE: BHSC) (“BioHarvest” or the “Company”) has reached an important milestone in its development program of additional Nutraceuticals. The olive-based Nutraceutical product scheduled for market availability in the second half of 2022 will contain the following unique matrix of polyphenols: hydroxytyrosol, trosol, and verbascoside. These compounds are the major polyphenols in naturally grown olives and are responsible for the high antioxidant activity of olives and olive oil. Importantly, the BioHarvest olive-based Nutraceutical product will provide all the benefits of olives and olive oil with a low calorie count per serving.

Keep reading... Show less

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today that it will report financial results for the fourth quarter and full year ended December 31 st , 2020 on Thursday March 25 th , 2021 before the market opens.

The Company will host a conference call and webcast to discuss its financial results and provide investors with key business highlights on Thursday March 25 th , 2021 at 8:30am Eastern Time (7:30am Central Time).

Keep reading... Show less

 Canopy Growth Corporation (TSX: WEED) (NASDAQ: CGC) (“Canopy Growth” or “the Corporation”) announced today that EVP & CFO Mike Lee will be participating in a fireside chat at the BofA Securities Virtual Consumer & Retail Technology Conference on Thursday, March 11, 2021 at 9:30am ET .

Keep reading... Show less

Hill Street Beverage Company Inc. (TSXV: BEER) (“Hill Street” or the “Company”). The Company announces that further to its press release dated March 2, 2021, it has obtained TSX Venture Exchange approval to extend the closing date of its previously announced private placement of units (“Units”) until April 7, 2021. Each Unit is comprised of one (1) common share and one (1) warrant, exercisable for one common share at price of $0.11 per share, for a period of three (3) years from the date of Closing. The Company applied to extend the date of closing to allow a greater number of interested investors to participate.

For more information regarding the Company or the offering, please contact ir@hillstreetbevco.com, or

Keep reading... Show less